Can you take Modafinil and Adderall (amphetamine salts) together?

The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

Rankings / Comparisons

Modafinil vs Adderall (amphetamine salts)

Wakefulness promoter vs prescription stimulant — overlapping use cases, very different mechanisms and risks.

Reviewed by Read Off Label · How we grade

Score comparison

Modafinil has the higher descriptive composite (B+, 7.4/10) compared with Adderall (amphetamine salts) (C+, 5.4/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.

Modafinil

B+ 7.4/10

aka Provigil

Evidence: Strong (narcolepsy, shift-work disorder, OSA residual sleepiness); Moderate (cognitive enhancement in sleep-deprived; small effect in rested) (8/10)
Benefit: Med-High (6.5/10)
Risk: Low-Med (headache, insomnia, rare but serious SJS/TEN; mild dependence potential) (7/10 safety)
Legality: Rx (Schedule IV US)
Dose / route context: 100-400 mg PO once daily morning
Class: Prescription
Last reviewed: Aug 13, 2026

Read Off Label grades Modafinil as B+ (7.4/10) based on strong evidence, med-high benefit magnitude, and a low-med-risk safety profile.

Battleday & Brem 2015 reviewed ~24 studies; benefits most consistent on tasks requiring sustained attention and executive function.

Studied, labeled, or reported-use context: 100-400 mg PO once daily morning — Rx; not individualized guidance.

What it is

Battleday & Brem 2015 reviewed ~24 studies; benefits most consistent on tasks requiring sustained attention and executive function. Minor US Schedule IV scheduling. Popular off-label cognitive enhancer among knowledge workers and military. Reduces sleep pressure markers.

Mechanism

Weak DAT inhibitor; complex orexinergic, histaminergic, glutamatergic, and GABAergic effects; promotes wakefulness with lower abuse potential than amphetamines

Full Modafinil review →

Adderall (amphetamine salts)

C+ 5.4/10

Evidence: Strong (ADHD); Moderate (cognitive enhancement — small effect in healthy) (8/10)
Benefit: Med-High (6.5/10)
Risk: High (addiction/dependence potential; BP/HR; anxiety; Schedule II) (2/10 safety)
Legality: Rx (Schedule II)
Dose / route context: IR: 5-40 mg/day in divided doses; XR: 10-30 mg/day
Class: Prescription
Last reviewed: Aug 13, 2026

Read Off Label grades Adderall (amphetamine salts) as C+ (5.4/10) based on strong evidence, med-high benefit magnitude, and a high-risk safety profile.

Its high-risk evidence profile reflects a Safety score of 2/10; reported benefits and harms can differ by indication, dose, route, duration, and population.

Gold-standard ADHD treatment.

Studied, labeled, or reported-use context: IR: 5-40 mg/day in divided doses; XR: 10-30 mg/day — Rx; not individualized guidance.

What it is

Gold-standard ADHD treatment. In healthy individuals, benefits mostly limited to specific tasks (working memory, sustained attention) with small effect sizes. Tolerance develops. Cardiovascular risk is real, especially long-term.

Mechanism

Mixed amphetamine salts; potent DAT/NET reuptake inhibitor and TAAR1 agonist; also reverses transporter direction to force catecholamine release; elevated dopamine and norepinephrine in PFC

Full Adderall (amphetamine salts) review →

Common questions

How do the evidence profiles of Modafinil and Adderall (amphetamine salts) compare?: Modafinil has the higher descriptive composite (B+, 7.4/10) compared with Adderall (amphetamine salts) (C+, 5.4/10). The axes below show whether that difference comes from evidence, reported benefit, safety, or a combination.
What's the difference between Modafinil and Adderall (amphetamine salts)?: Wakefulness promoter vs prescription stimulant — overlapping use cases, very different mechanisms and risks.
Can you take Modafinil and Adderall (amphetamine salts) together?: The available evidence is use- and population-specific. Each page documents mechanism, studied or reported dose context, risks, and legal status; the database does not determine whether a combination is appropriate for an individual.

This is an independent synthesis of published research by a non-clinician. The comparison reports composite and axis-level differences without selecting an intervention for the reader. Relevance depends on indication, population, dose, duration, and other context. See the full disclaimer and methodology.